Skip to main content

New hope treatment in familial hypercholesterolemia

New hope comes today for those with familial hypercholesterolemia (FH).

Familial hypercholesterolemia (FH) is a genetic disorder characterized by high cholesterol levels, specifically very high levels of low-density lipoprotein (LDL, "bad cholesterol"), in the blood and early cardiovascular disease.



Without treatment, the life expectancy of those with familial hypercholesterolemia can be reduced by approximately 15-30 years. However, in people with homozygous familial hypercholesterolemia, life expectancy may only be 20 years or less.

Homologous chromosomes come in pairs. One homologous chromosome is inherited from the mother; the other is inherited from the father.  Homozygous refers to a gene that has identical alleles on both homologous chromosomes.   This is why the homozygous condition is particularly rare and can be more severe.

HoFH is a rare and more severe form of familial hypercholesterolemia (FH), an inherited condition characterized by very high levels of LDL-C and premature cardiovascular disease.

Inheriting FH- causing mutations from both parents results in HoFH in the child. HoFH is an extremely severe condition and is often associated with aggressive and markedly premature heart disease, including coronary artery disease and aortic valve disease. 

Children and teenagers with HoFH may have heart attacks or angina requiring the insertion of coronary stents or heart bypass surgery.

A new study shows that adding Praluent® (alirocumab) significantly reduced cholesterol levels by 35.6 per cent, compared to other lipid-lowering therapies alone, in patients with homozygous familial hypercholesterolemia.

The results of the placebo-controlled trial were presented at the joint meeting of the American College of Cardiology (ACC.20) together with the World Congress of Cardiology (WCC) Scientific Sessions.

Results showed treatment with Praluent significantly reduced other lipoprotein and lipid measures associated with elevated cardiovascular risk, including apolipoprotein B [29.8 percent (p<0.0001)], total cholesterol [26.5 percent (p<0.0001)], non-high-density lipoprotein cholesterol (HDL-C) [32.9 percent (p<0.0001)] and lipoprotein(a) [28.4 percent (p<0.0001)] versus placebo.

Lead investigator Dr Dirk Blom says,

“These results demonstrate a statistically significant and clinically-meaningful reduction in LDL-C levels after 12 weeks and have the potential to expand treatment options for very high-risk patients with this serious condition.”



Comments

Popular posts from this blog

Ian Duncan-Smith says he wants to make those on benefits 'better people'!

By any account, the government's austerity strategy is utilitarian. It justifies its approach by the presumed potential ends. It's objective is to cut the deficit, but it has also adopted another objective which is specifically targeted. It seeks to drive people off benefits and 'back to work'.  The two together are toxic to the poorest in society. Those least able to cope are the most affected by the cuts in benefits and the loss of services.

It is the coupling of these two strategic aims that make their policies ethically questionable. For, by combining the two, slashing the value of benefits to make budget savings while also changing the benefits system, the highest burden falls on a specific group, those dependent on benefits. For the greater good of the majority, a minority group, those on benefits, are being sacrificed; sacrificed on the altar of austerity. And they are being sacrificed in part so that others may be spared.

Utilitarian ethics considers the balan…

Keir Starmer has a lot to offer

The Labour Party is in the process of making a decision that will decide whether it can recover from the defeat in 2019 General Election.  All the candidates have much to offer and are making their case well.

No doubt for some the decision will be difficult.  Others may well have made up their minds on the simple binary of Left-wing-Right-wing.

The choice should be whoever is best placed to pull the party together.  Someone who can form a front bench of all talents and across the spectrum in the party.

That is what Harold Wilson did in the 1960s.  His government included Roy Jenkins on the right and Barbar Castle on the left; it included Crossman and Crossland, and Tony Benn with Jim Callaghan.  It presented a formidable team.

Keir Starmer brings to the top table a formidable career outside politics, having been a human rights lawyer and then Director of Public Prosecutions.   He is a man of integrity and commitment who believes in a fairer society where opportunities are more widel…

No evidence for vaccine link with autism

Public health bodies are worried that an alarming drop in childhood vaccinations is leading to a resurgence of diseases in childhood that we had all but eradicated.  Misinformation and scare stories about the harmful effects of vaccines abound on the internet and in social media.  Where they are based on 'science', it is highly selective, and often reliance is placed on falsehoods. 
Conspiracy theories also abound - cover-ups, deception, lies. As a result, too many parents are shunning vaccinations for their children.  So, what does the published, peer-reviewed literature tell us about vaccincations? Are they safe and effective, or are there long term harmful effects? 
A new report now provides some of the answers.

New evidence published in the Cochrane Library today finds MMR, MMRV, and MMR+V vaccines are effective and that they are not associated with increased risk of autism.

Measles, mumps, rubella, and varicella (also known as chickenpox) are infectious diseases caused by …